Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases
WO2021016462A1
The peptidomimetic compound (r)-2-amino-n-((s)-l-(((s)-5-amino-l-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-i-oxopropan-2-yl)-5-guanidinopentanamide in the treatment of neurodegenerative diseases
WO2020118035A1
Methods and compositions for the treatment of sengers syndrome
WO2020131283A1
Analogs that target mitochondrial diseases
WO2020131282A1
Mitochondria-targeting peptides
US2020157145A1
Neutral-cationic peptoids and uses thereof
WO2020018455A1
Compositions and methods for the treatment of traumatic optic neuropathy
AU2019249121A1
Crystalline dipeptides useful in the synthesis of elamipretide
US2019233474A1
Crystalline bis- and tris-hydrochloride salt of elamipretide
KR20200115493A
Mitochondrial-targeting peptide
US2020361987A1
Deuterated tetrapeptides that target mitochondria
WO2018223032A1
Crystalline salt forms of sbt-20
WO2018187400A1
Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
CA2995096A1
Therapeutic compositions including mitochondrial cell-penetrating peptides, glutathione analog peptides, and fusions thereof, and uses of the compositions to treat and prevent mitochondrial diseases and conditions
CA2984407A1
Therapeutic compositions including triterpenoid and uses thereof to treat and prevent mitochondrial diseases and conditions
KR20190089846A
N-carboxyanhydride-based-scale synthesis of elramipredide
CA2973885A1
Therapeutic compositions including mitochondrial-targeted creatine compounds and uses thereof to treat and prevent mitochondrial diseases and conditions
CA2973891A1
Therapeutic compositions including modified creatine compounds and uses thereof to treat and prevent mitochondrial diseases and conditions
AU2017267969A1
Compositions and methods for the prevention and treatment of mitochondrial myopathies
